Key Highlights

  • Cue Biopharma shares ended the day down 19% at $27.64.
  • The company disclosed a widened Q2 net loss of $153.1 million.
  • The loss was heavily impacted by CUE-221 licensing fees and non-cash Acquisition costs.
  • A Boehringer Ingelheim milestone boosted quarterly Revenue to $7.9 million.

Cue Biopharma, Inc. (NASDAQ: CUE) shares ended the day down 19% at $27.64 after the company disclosed a widened Q2 net loss of $153.1 million, a figure heavily impacted by CUE-221 licensing fees and non-cash acquisition costs.

What Happened

Even as a Boehringer Ingelheim milestone boosted quarterly revenue to $7.9 million, the market now anticipates Phase 2 data for CUE-221 in CSU by the close of Q3 2026, alongside a projected IND submission and Phase 1 start for CUE-401 later this year.

Market Reaction

Shares fell sharply as investors focused on the scale of the widened net loss, despite the offsetting boost to revenue from the Boehringer Ingelheim milestone payment.

Outlook

Phase 2 data for CUE-221 in chronic spontaneous urticaria, expected by the close of the third quarter of 2026, along with the projected IND submission and Phase 1 start for CUE-401 later this year, represent the next major disclosed milestones for Cue Biopharma.